Literature DB >> 30849254

Biological changes in C57BL/6 mice following 3 weeks of inhalation exposure to cigarette smoke or e-vapor aerosols.

K Monica Lee1, Julia Hoeng2, Sam Harbo3, Ulrike Kogel2, William Gardner1, Michael Oldham1, Eric Benson3, Marja Talikka2, Athanasios Kondylis2, Florian Martin2, Bjoern Titz2, Sam Ansari2, Keyur Trivedi2, Emmanuel Guedj2, Ashraf Elamin2, Nikolai V Ivanov2, Patrick Vanscheeuwijck2, Manuel C Peitsch2, Willie J McKinney1.   

Abstract

We compared early biological changes in mice after inhalation exposures to cigarette smoke or e-vapor aerosols (MarkTen® cartridge with Carrier, Test-1, or Test-2 formulations; 4% nicotine). Female C57BL/6 mice were exposed to 3R4F cigarette smoke or e-vapor aerosols by nose-only inhalation for up to 4 hours/day, 5 days/week, for 3 weeks. The 3R4F and e-vapor exposures were set to match the target nose port aerosol nicotine concentration (∼41 µg/L). Only the 3R4F group showed postexposure clinical signs such as tremors and lethargy. At necropsy, the 3R4F group had significant increases in lung weight and changes in bronchoalveolar lavage parameters, as well as microscopic findings in the respiratory tract. The e-vapor groups had minimal microscopic changes, including squamous metaplasia in laryngeal epiglottis, and histiocytic infiltrates in the lung (Test-2 group only). The 3R4F group had a higher incidence and severity of microscopic findings compared to any e-vapor group. Transcriptomic analysis also showed that the 3R4F group had the highest number of differentially expressed genes compared to Sham Control. Among e-vapor groups, Test-2 group had more differentially expressed genes but the magnitude of gene expression-based network perturbations in all e-vapor groups was ∼94% less than the 3R4F group. On proteome analysis in the lung, differentially regulated proteins were detected in the 3R4F group only. In conclusion, 3-weeks of 3R4F exposure induced molecular and microscopic changes associated with smoking-related diseases in the respiratory tract, while e-vapor exposures showed substantially reduced biological activities.

Entities:  

Keywords:  3R4F; MarkTen®; aerosols; e-cigarette; e-vapor; inhalation; mice; proteomics; transcriptomics

Mesh:

Substances:

Year:  2019        PMID: 30849254     DOI: 10.1080/08958378.2019.1576807

Source DB:  PubMed          Journal:  Inhal Toxicol        ISSN: 0895-8378            Impact factor:   2.724


  10 in total

Review 1.  Recent findings in the pharmacology of inhaled nicotine: Preclinical and clinical in vivo studies.

Authors:  Asti Jackson; Ben Grobman; Suchitra Krishnan-Sarin
Journal:  Neuropharmacology       Date:  2020-06-24       Impact factor: 5.250

2.  Electronic cigarette exposure disrupts blood-brain barrier integrity and promotes neuroinflammation.

Authors:  Nathan A Heldt; Alecia Seliga; Malika Winfield; Sachin Gajghate; Nancy Reichenbach; Xiang Yu; Slava Rom; Amogha Tenneti; Dana May; Brian D Gregory; Yuri Persidsky
Journal:  Brain Behav Immun       Date:  2020-03-31       Impact factor: 7.217

Review 3.  Toxicology of flavoring- and cannabis-containing e-liquids used in electronic delivery systems.

Authors:  Aleksandr B Stefaniak; Ryan F LeBouf; Anand C Ranpara; Stephen S Leonard
Journal:  Pharmacol Ther       Date:  2021-03-18       Impact factor: 13.400

Review 4.  What are the respiratory effects of e-cigarettes?

Authors:  Jeffrey E Gotts; Sven-Eric Jordt; Rob McConnell; Robert Tarran
Journal:  BMJ       Date:  2019-09-30

5.  Fundamentals of vaping-associated pulmonary injury leading to severe respiratory distress.

Authors:  Carolina Esquer; Oscar Echeagaray; Fareheh Firouzi; Clarissa Savko; Grant Shain; Pria Bose; Abigail Rieder; Sophie Rokaw; Andrea Witon-Paulo; Natalie Gude; Mark A Sussman
Journal:  Life Sci Alliance       Date:  2021-11-22

6.  Combined biological effects and lung proteomics analysis in mice reveal different toxic impacts of electronic cigarette aerosol and combustible cigarette smoke on the respiratory system.

Authors:  Wanchun Yang; Xuemin Yang; Lujing Jiang; Hongjia Song; Guangye Huang; Kun Duan; Xingtao Jiang; Min Li; Peiqing Liu; Jianwen Chen
Journal:  Arch Toxicol       Date:  2022-09-29       Impact factor: 6.168

7.  Assessment of inhalation toxicity of cigarette smoke and aerosols from flavor mixtures: 5-week study in A/J mice.

Authors:  Ee Tsin Wong; Karsta Luettich; Lydia Cammack; Chin Suan Chua; David Sciuscio; Celine Merg; Maica Corciulo; Romain Piault; Kumar Ashutosh; Cameron Smith; Patrice Leroy; Fabian Moine; Anneke Glabasnia; Pierrick Diana; Cecilia Chia; Ching Keong Tung; Nikolai Ivanov; Julia Hoeng; Manuel Peitsch; Kyeonghee Monica Lee; Patrick Vanscheeuwijck
Journal:  J Appl Toxicol       Date:  2022-06-08       Impact factor: 3.628

Review 8.  A Summary of In Vitro and In Vivo Studies Evaluating the Impact of E-Cigarette Exposure on Living Organisms and the Environment.

Authors:  Anna Merecz-Sadowska; Przemyslaw Sitarek; Hanna Zielinska-Blizniewska; Katarzyna Malinowska; Karolina Zajdel; Lukasz Zakonnik; Radoslaw Zajdel
Journal:  Int J Mol Sci       Date:  2020-01-19       Impact factor: 5.923

9.  Use of micro-CT to determine tracheobronchial airway geometries in three strains of mice used in inhalation toxicology as disease models.

Authors:  Michael J Oldham; Francesco Lucci; Clement Foong; Demetrius Yeo; Bahman Asgharian; Steve Cockram; Stephen Luke; Joanne Chua; Julia Hoeng; Manual C Peitsch; Arkadiusz K Kuczaj
Journal:  Anat Rec (Hoboken)       Date:  2021-03-06       Impact factor: 2.064

10.  Impact of whole-body versus nose-only inhalation exposure systems on systemic, respiratory, and cardiovascular endpoints in a 2-month cigarette smoke exposure study in the ApoE-/- mouse model.

Authors:  Ulrike Kogel; Ee Tsin Wong; Justyna Szostak; Wei Teck Tan; Francesco Lucci; Patrice Leroy; Bjoern Titz; Yang Xiang; Tiffany Low; Sin Kei Wong; Emmanuel Guedj; Nikolai V Ivanov; Walter K Schlage; Manuel C Peitsch; Arkadiusz Kuczaj; Patrick Vanscheeuwijck; Julia Hoeng
Journal:  J Appl Toxicol       Date:  2021-04-06       Impact factor: 3.446

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.